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Abstract
Erectile dysfunction (ED) is associated with cardiovascular disease (CVD) and CVD mortality. However, the relationship
between ED and subclinical CVD is less clear. We synthesized the available data on the association of ED and measures
of subclinical CVD. We searched multiple databases for published literature on studies examining the association of ED
and measures of subclinical CVD across four domains: endothelial dysfunction measured by flow-mediated dilation (FMD),
carotid intima–media thickness (cIMT), coronary artery calcification (CAC), and other measures of vascular function such
as the ankle–brachial index, toe–brachial index, and pulse wave velocity. We conducted random effects meta-analysis
and meta-regression on studies that examined an ED relationship with FMD (15 studies; 2025 participants) and cIMT
(12 studies; 1264 participants). ED was associated with a 2.64 percentage-point reduction in FMD compared to those
without ED (95% CI: –3.12, –2.15). Persons with ED also had a 0.09-mm (95% CI: 0.06, 0.12) higher cIMT than those
without ED. In subgroup meta-analyses, the mean age of the study population, study quality, ED assessment questionnaire
(IIEF-5 or IIEF-15), or the publication date did not significantly affect the relationship between ED and cIMT or between
ED and FMD. The results for the association of ED and CAC were inconclusive. In conclusion, this study confirms an
association between ED and subclinical CVD and may shed additional light on the shared mechanisms between ED and
CVD, underscoring the importance of aggressive CVD risk assessment and management in persons with ED.
Keywords
endothelial dysfunction, erectile dysfunction, subclinical cardiovascular disease, carotid intima-media thickness (cIMT),
coronary artery calcification

Introduction
Despite concerted preventive efforts, cardiovascular disease (CVD) continues to be the leading cause of mortality
globally.1 Sixty-six percent of these deaths can be attributed
to atherosclerotic CVD (ischemic heart disease, ischemic
stroke, and peripheral vascular disease).1,2 As a response to
the significant burden of CVD, there has been increased
focus on traditional CVD risk factor identification and risk
stratification, with the hope of identifying persons that are
most likely to benefit from prevention therapy.
Subclinical CVD independently predicts CVD events,
and its absence is associated with minimal CVD risk, even in
the presence of other traditional risk factors.3–8 Thus, subclinical CVD assessment is often used as an adjunct to traditional CVD risk stratification. Several non-invasive methods
of assessing subclinical CVD have been developed, with the
most popular being the coronary artery calcium (CAC)
score,9 a marker of coronary atherosclerosis, and carotid
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intima–media thickness (cIMT), a marker of the arteriosclerosis and atherosclerosis of the carotid arteries.10 Markers
of endothelial function, such as brachial artery flow-mediated dilation (FMD) and the reactive hyperemia index
(RHI),11,12 as well as other markers of vascular function, are
also used to assess subclinical CVD in research settings.13
Erectile dysfunction (ED) is a common disorder with an
overall prevalence of around 18% in men aged 20 or more
years.14 The proportion of ED by cause has not been well
described in the literature. However, a small series with 69
participants indicated that a vascular disorder (evaluated by
penile color Doppler ultrasound) was associated with ED in
about 34% of non-hypogonadal, non-neuropsychiatric
patients.15 In multiple studies including systematic reviews,
ED has been shown to be associated with an increased risk of
CVD.16–18
ED and subclinical CVD have similar risk factors (age,
obesity, smoking),19 and it is thought that both conditions
have shared mechanisms. However, the relationship
between ED and subclinical CVD is not as clear as that for
established CVD as the studies examining this association
are limited by less than ideal sample sizes, and have had
conflicting results. Particularly, it is unknown which markers of subclinical CVD have the greatest or most consistent
association with ED.
Delineating a consistent, strong association of ED with
subclinical CVD will help in establishing ED as a simple
and effective marker of underlying subclinical CVD. In
such an instance, measures of ED could be a simple effective CVD risk stratification tool, particularly in young men
who are less likely to undergo aggressive CVD risk assessment and management. This systematic review and metaanalysis is aimed at examining and synthesizing the current
evidence describing the relationship between ED and measures of subclinical CVD with a view to highlighting the
strength of the associations where possible and to identify
gaps in knowledge for future research.

Methods
We systematically searched PubMed, Excerpta Medica
Database (EMBASE), Web of Science, Cumulative Index
to Nursing, Allied Health Literature (CINAHL), the
Cochrane Library of Trials, and Scopus for published studies assessing the association of ED and markers of subclinical CVD between 1964 and 2016. As part of our search
strategy, we divided vascular markers into four domains:
endothelial function, carotid atherosclerosis, coronary atherosclerosis, and other markers of vascular function (ankle–
brachial index (ABI), pulse wave velocity (PWV), and
toe–brachial index (TBI)). In addition to ED, search terms
were generated to represent each domain and include variations of the following: coronary artery calcification,
carotid intima–media thickness, flow-mediated dilatation,
brachial reactivity, reactive hyperemia index, ankle–brachial
index, toe–brachial index, and pulse wave velocity. We
excluded studies with non-standardized assessments of ED,
those whose participants had known CVD, and studies
without comparison groups for ED. We also excluded case
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reports and case-series, studies without full text and those
whose full text were not in English. One reviewer conducted the search (BV) and two reviewers assessed studies
for eligibility (BV and EA). Only studies that were agreed
upon by both reviewers as meeting the specified eligibility
criteria were included in the review.

Erectile dysfunction assessment
To be included in the review, the study had to have a standardized measurement of ED (a validated questionnaire or
other clinically acceptable measure) and a subclinical
marker of CVD in at least one of the earlier mentioned
domains. ED and its severity are most frequently assessed
using the International Index of Erectile Function questionnaires. The IIEF-15 is a 15-item questionnaire that assesses
four domains of male sexual function. The IIEF-5 is an
abridged version of the original 15-item questionnaire.
Both of these questionnaires are validated, have a high
degree of sensitivity and specificity for detecting ED, and
are widely used in research studies.20,21

Description of outcome measures
Endothelial dysfunction is most commonly assessed by
flow-mediated dilation (FMD) of the brachial artery. FMD,
most often assessed in the brachial artery, is captured by
ultrasonographic measure of changes in vessel diameter
over a period of time (often 60 seconds) after deflation of a
cuff placed around the vessel. These changes are measured
as percentage difference from baseline.11 The cIMT is
measured by ultrasound assessment of either the common
carotid artery or the internal carotid arteries, or both,22 and
is expressed in millimeters (mm). CAC is measured by a
computed tomography (CT) scan assessment of the coronaries and algorithms are used to determine its standardized
Agatston score.9 PWV is a measure of arterial stiffness; the
aortic PWV is more of a measure of central arterial stiffness
while the brachial–ankle measures peripheral arterial stiffness. ABI and TBI, both measured by Doppler assessment
of systolic pressures in the lower and upper extremities, are
often used to determine peripheral artery disease and can be
used as markers of subclinical CVD in persons who have
no clinical symptoms of CVD.23

Assessment of study quality
We formally assessed all studies for quality using the
‘Quality Assessment Tool for Observational Cohort and
Cross-Sectional Studies’ developed by the National
Institutes of Health and freely available on the Internet.24
This 14-item scoring tool was developed for longitudinal,
cross-sectional and case–control studies (Supplementary
Table 1). Each item was scored ‘1’ for ‘Yes’ or met criteria
or ‘0’ for ‘No’ or did not meet criteria. For questions
whose answers could not be deciphered from the published study, ‘UA’ (unable to assess) was given, while
‘N/A’ was given for questions that were not applicable
(such as questions asking about loss to follow-up in
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Figure 1. Systematic review search results.

studies that are cross-sectional or case–control). Two
reviewers (CUO and EA) independently assessed quality
for each study and disagreements on scoring were settled
by discussion. A numeric score was assigned to each study
based on the total number of items scored ‘1’. We decided
that studies with scores of 10 or more were of high quality,
those with 7–10 were intermediate quality, while those
with less than 7 were deemed to be of lower quality. A
summary of the assessment of included studies can be
found in the Supplementary Table 2.

Meta-analysis
We decided a priori to conduct a meta-analysis if there were
three or more studies with comparable outcomes. We considered outcomes comparable if the measures of subclinical
CVD were the same, had similar categorizations if and
where applicable, and had similar units of measurements.
Only FMD and cIMT met these criteria. The data from each
study included in the meta-analysis were manually extracted
and copied into an Excel sheet. All statistical analyses were
performed using the software package R (Version 3.1.1; R
Foundation for Statistical Computing, Vienna, Austria). The
R function metacont and metareg in package meta25 was
used for the meta-analysis of the continuous outcomes (i.e.
FMD (measured as percentage change in brachial arterial
dilation) and cIMT (measured in mm)). Inverse variance
weighting was used for pooling, absolute mean differences
(referred to as mean difference from on) were generated and
the results from random effects models26 are presented with
their corresponding forest plots. Measures of heterogeneity
(I2) and between study variance (τ2; tau-squared) are also

reported. Owing to the presence of significant heterogeneity
encountered with the meta-analysis, we sought to determine
the source(s) of this heterogeneity. Therefore, subgroup
meta-analyses were conducted to assess the influences of
age, ED assessment type (short vs standard form of the
IIEF), study publication date and study quality on the results
of the meta-analysis. We also conducted a sensitivity analysis sequentially excluding the three studies that deviated the
most from the absolute mean difference (and seen as outliers
in the forest plot) in each meta-analysis. To assess for the
risk of publication bias, a funnel plot of the studies was generated and a formal test of asymmetry, the weighted linear
regression of the treatment effect on its standard error,27 was
conducted.

Results
Figure 1 describes the results of the search. A total of 28
studies met the criteria for inclusion in the review. Many of
the included studies measured multiple subclinical CVD
outcomes. In all, 15 studies examined endothelial dysfunction as an outcome, with all these measuring FMD and
none measuring RHI.28–42 Twelve studies examined cIMT
outcomes,28,34,35,38,40,42–48 five studies measured CAC28,29,37,49,50
and six studies had various measures of vascular stiffness
and peripheral vascular disease such as PWV, Augmentation
Index (AIx), ABI, and TBI.28,51–55 All the studies with FMD
(n=15) and cIMT (n=12) outcomes were included in the
meta-analysis regardless of their quality. None of the other
outcome measures met our a priori meta-analysis criteria.
Among the CAC studies, two compared continuous measures of CAC (mean and median) between ED groups, while
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the others were binary but had inconsistent cut-offs for
abnormal CAC values. Among the other measures of vascular function, three studies measured ABI: two were continuous outcomes and one was binary. No other measure of
vascular function was assessed in three or more studies. All
studies included in this review were either case–control or
cross-sectional studies; no longitudinal studies met the
inclusion criteria. The description of the studies, grouped by
their subclinical CVD outcomes, can be found in Table 1.

Erectile dysfunction and flow-mediated dilation
As shown in Figure 2, the meta-analysis of the association
between ED and FMD demonstrates a significant relationship between ED and FMD. A total of 15 studies with 2025
participants examined the relationship between ED and
FMD.28–42 They all measured brachial FMD; however, the
methods of FMD assessment were not universal among the
studies. Seven of the 15 studies had the cuff placed on the
forearm (including one which described the wrist),28–32,37,39
while the others either had the cuff inflated over the
arm36,38,40,42 or did not specify.33–35,41 In addition, the inflating pressures were inconsistent as studies reported pressures between 250 mmHg and 300 mmHg,28,30–32,38,40,42
while others had cuff pressures 50 mmHg above the systolic BP.29,33–36,39 One study had cuff pressures at least 100
mmHg above the systolic BP.37 Cuff occlusion lasted for
4–5 minutes in most of the studies and the brachial artery
diameter was measured at baseline and at 30–90 seconds
post cuff occlusion in most studies. ED was assessed using
the International Index of Erectile Function questionnaire
(IIEF-15, five studies) or its short form (IIEF-5, ten
studies). Using a random-effects model (REM), the metaanalysis of the pooled studies showed that persons with
ED had FMD 2.6 percentage points less than those without
ED (mean difference –2.64; 95% confidence interval (CI):
–3.12, –2.15). There was significant between-study variability, with an I2 of 97% (Figure 2). In sensitivity analysis,
sequential exclusion of the three most deviated studies
resulted in a minimal change in the overall heterogeneity
(I2 = 97.0%; p-value ≤ 0.001) (Supplementary Table 3). In
subgroup meta-analyses, the mean difference was significantly different in age and study quality groups. However,
none of the subgroups within any of the groups had a different direction of association, making them unlikely to
have accounted in entirety for the significant heterogeneity
between studies (see Table 2). More details on the results
of the subgroup meta-analyses are shown in Supplementary
Figures 1–4.

Erectile dysfuntion and carotid intima-media
thickness
Figure 3 shows a forest plot for the meta-analysis of the
association between ED and cIMT. Overall, a significant
association is demonstrated. Twelve studies with 1264
participants assessed the relationship between ED and
cIMT.28,34,35,38,40,42–48 Eight of these studies assessed IMT
in the common carotid arteries,28,34,35,42–44,46,48 one study
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measured IMT at the common carotid, carotid bifurcation
and the proximal internal carotid artery on each side,43
while no location was specified in three studies.38,40,45,47
The methods of assessing ED were also the IIEF-15
(seven studies) and the IIEF-5 (five studies). Persons with
ED had significantly greater cIMT (0.09 mm) than those
without ED (mean difference: 0.09 mm; 95% CI: 0.06
mm, 0.12 mm). There was also substantial heterogeneity
between cIMT studies (I2 = 73%). In a subgroup metaanalysis, neither age, ED questionnaire type, study quality, nor publication year was a source of heterogeneity, as
there was statistical similarity in the mean difference
within these groups. Details of the subgroup meta-analysis results can be seen in Table 2. More details on the
subgroup meta-analysis are shown in Supplementary
Figures 5–8. In sensitivity analysis, exclusion of the three
most influential studies revealed an attenuation of heterogeneity among studies that was statistically non-significant (I2 = 0%; p-value = 0.75) (Supplementary Table 3).
The study by Kaiser et al.28 appears to be most responsible
for the heterogeneity observed in this meta-analysis, as
exclusion of this study alone resulted in more than a 25%
drop in I2 (71% to 21%, see Supplementary Table 3).

Erectile dysfunction and coronary artery
calicification
Five studies examined the association between ED and
CAC28,29,37,49,50 (Table 3). Two of the five studies showed a
significant association between ED and CAC.29,49 Both of
these studies demonstrated greater CAC burden among
those with ED compared to those without ED. In general,
all the CAC studies had sample sizes less than 200.

Erectile dysfunction and other measures of
vascular function
Six studies assessed the relationship between ED and other
various measures of vascular function (some studies assessed
vascular function using more than one measure).28,51–55
Among the three studies that examined the relationship
between ED and ABI, two of them demonstrated no association with ABI, while one study showed that the prevalence of ED was two times higher among persons with an
ABI ≤0.9 than those with an ABI >0.9. Both studies showing no association between ED and ABI were conducted in
primarily diabetic populations.
Only two studies examined the association between ED
and TBI, with both studies showing similar results. One of
these studies determined that ED was significantly associated with a lower TBI, while the other showed that lower
scores on the IIEF-5 (increased likelihood of ED) were
associated with a lower TBI.
Similar to TBI, two studies assessed the association of
ED and BAPWV, with both studies showing that ED was
significantly associated with this marker of vascular
function. However, the only study that assessed the relationship with AoPWV did not show any significant
association.
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Table 1. Description of studies included in the review.
Author

Publication Population
year

ENDOTHELIAL DYSFUNCTION
2004
30 men with ED, 27 ageKaiser28
matched men without ED
Chiurlia29
2005
70 men with vascular ED,
73 men with no history
of CAD
2005
75 men with CV risk
Yavuzgil30
factors (36 with ED, 39
without ED), 25 with no
CV risk factors
2005
32 men with ED, 25
Kaya31
healthy men without ED
35 men with ED/, 15
healthy men without ED
Stuckey33
2007
49 men with ED, 50 agematched men without ED
Vlachopoulos34 2008
52 hypertensive men with
vasculogenic ED, 34
age-matched HT men
without ED
2011
100 sexually active men
Javaroni35
with HT (74 had ED, 26
had no ED)
2012
34 men with ED, 18 ageAverbeck36
matched men without ED
Guaraldi37
2012
133 HIV-infected men (79
had ED, 54 had no ED)
Yao38
2012
122 patients with ED, 33
age-matched men
without ED
2012
100 men with diabetes,
Murata39
Type II (42 had ED, 58
had no ED)
2013
192 men with ED, 32 men
Yao40
without ED
Gerber41
2015
111 men ED, 279 men
without ED
Chen42
2016
261 men with ED, 40 men
without ED
CAROTID INTIMA–MEDIA THICKNESS
Kaiser28
2004
30 men with ED, 27 agematched men without ED
Bocchio43
2004
45 only with ED, 25
without ED
Vlachopoulos34 2008
52 hypertensive men
with vasculogenic ED,
34 age-matched HT men
without ED
2008
15 men with ED, 15 men
Vicenzini44
without ED
Stolic45
2010
73 men treated with
chronic hemodialysis for
over 3 months (60 had
ED, 13 had no ED)
2011
100 sexually active men
Javaroni35
with HT (74 had ED, 26
had no ED)
2012
122 patients with ED, 33
Yao38
age-matched men
without ED
Mazo32

2006

Age range
(average)

Study
description

Measures of
subclinical CVD

ED
assessment

(46.6, 46.2)

Case–control

Brachial FMD

IIEF-15

(50.9, 50.1)

Case–control

Brachial FMD

IIEF-5

(54.4, 53, 52.4)

Case–control

Brachial FMD

IIEF-15

(55, 57)

Case–control

Brachial FMD

21–80 (51.2)

Cross-sectional Brachial FMD

IIEF-5 / penile
Doppler
ultrasound
IIEF-15

40–70 (59, 56)

Case–control

Brachial FMD

IIEF-15

(61.4, 59.0)

Case–control

Brachial FMD

IIEF-5

50–70 (58.9, 60.6) Cross-sectional Brachial FMD

IIEF-15

(59.61, 56.18)

Case–control

IIEF-5

(50.06, 47.48)

Cross-sectional Brachial FMD

IIEF-15

(31.81, 29.82)

Case–control

Brachial FMD

IIEF-5

(64.3, 61.8)

Cross-sectional Brachial FMD

IIEF-5

(29.44, 29.82)

Case–control

Brachial FMD

IIEF-5

(61.8, 53.4)

Case–control

Brachial FMD

IIEF-5

(30.4, 30.5)

Case–control

Brachial FMD

IIEF-5

(46.6, 46.2)

Case–control

cIMT

IIEF-15

25–67 (44.6, 45.9) Case–control

cIMT

IIEF-15

(61.4, 59.0)

Case–control

cIMT

IIEF-5

(58, 59)

Case–control

cIMT

IIEF-15

(55.06, 51.75)

Cross-sectional cIMT

IIEF-15

50–70 (58.9, 60.6) Cross-sectional cIMT

IIEF-15

(31.81, 29.82)

IIEF-5

Case–control

Brachial FMD

cIMT

(Continued)
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Table 1. (Continued)
Author

Publication Population
year

Age range
(average)

Study
description

Measures of
subclinical CVD

ED
assessment

Yao40

2013

(29.44, 29.82)

Case–control

cIMT

IIEF-5

Case–control

cIMT

IIEF-5

(46.80, 48.2)

Case–control

cIMT

IIEF-15

(54.2, 52.4)

Case–control

cIMT

IIEF-5

(66.4, 60.2)

Case–control

cIMT

IIEF-5

(46.6, 46.2)

Case–control

CAC

IIEF-15

(50.9, 50.1)

Case–control

CAC

IIEF-5

41–77 (55.7, 53.2) Case–control

CAC

IIEF-15

192 men with ED, 32 men
without ED
Chen42
2016
261 men with ED, 40 men
without ED
Dženkevičiūtė46 2013
45 caucasian men who
were sexually active
in a marriage or stable
relationship (21 had ED,
24 had no ED)
2014
44 men with ED, 20 men
Arrabal-Polo47
without ED
Al-Ali48
2015
41 men with ED, 18 men
without ED
CORONARY ARTERY CALCIUM
Kaiser28
2004
30 men with ED, 27 agematched men without ED
Chiurlia29
2005
70 men with vascular ED,
73 men with no history
of CAD
2007
60 men presenting with
Yaman49
ED at clinic, 23 agematched men without ED
2008
35 men with chronic renal
Inci50
failure (29 had ED, 6 had
no ED)
2012
133 HIV-infected men (79
Guaraldi37
had ED, 54 had no ED)
OTHER MEASURES OF VASCULAR FUNCTION
Kaiser28
2004
30 men with ED, 27 agematched men without ED
Chai51
2009
185 caucasian men of
Rancho Bernardo, CA
(122 had ED, 63 had
no ED)
2009
690 men referred for
Polonsky52
stress testing without
known PAD (311 had
ED, 370 had no ED)
2010
280 healthy Japanese
Imai53
men in countryside
communities (95 had ED,
185 had no ED)
2011
197 men with diabetes,
Fukui54
Type II (183 had ED, 14
had no ED)
2011
197 men with diabetes,
Fukui54
Type II (183 had ED, 14
had no ED)
2011
197 men with diabetes,
Fukui54
Type II (183 had ED, 14
had no ED)
2014
114 men being treated
Severo55
for diabetes, Type II, and
HT (82 had ED, 32 had
no ED)

22–78 (51.6)

Cross-sectional CAC

IIEF-5

(50.06, 47.48)

Cross-sectional CAC

IIEF-15

(46.6, 46.2)

Case–control

IIEF-15

44–94 (71)

Cross-sectional TBI

IIEF-5

(60.9, 54.4)

Cross-sectional ABI

IIEF-15

20–83 (67, 54)

Cross-sectional Brachial–ankle
PWV

IIEF-5

30–80 (64.6)

Cross-sectional Brachial–ankle
PWV

IIEF-5

30–80 (64.6)

Cross-sectional ABI

IIEF-5

30–80 (64.6)

Cross-sectional TBI

IIEF-5

(56.7, 56.8)

Cross-sectional ABI

IIEF-5

Aortic PWV

ABI, ankle–brachial index; CAC, coronary artery calcium; CAD, coronary artery disease; cIMT, carotid intima–media thickness; CVD, cardiovascular
disease; ED, erectile dysfunction; FMD, flow-mediated dilatation; HIV, human immunodeficiency virus; HT, hypertension; IIEF, International Index of
Erectile Function; PAD, peripheral artery disease; PWV, pulse wave velocity; TBI, toe–brachial index.
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Figure 2. Meta-analysis of studies on the relationship between erectile dysfunction (ED) and flow-mediated dilatation (FMD).
Results are shown as differences in percentage change between ED and non-ED groups and their pooled mean difference (MD).

Assessment of publication bias
For the studies included in the meta-analysis (i.e. those assessing the association of ED with FMD and ED with cIMT) we
assessed the likelihood of publication bias by creating a funnel plot and conducting formal tests of asymmetry
(Supplementary Figures 9 and 10). In both FMD and cIMT
studies, linear regression tests of funnel plot asymmetry were
not statistically significant, indicating a lower likelihood of
publication or other bias.

Discussion
In this systematic review and meta-analysis, we demonstrate that ED is associated with subclinical CVD in most,
but not all studies. The evidence is strongest for the association of ED with poor endothelial function (measured by
FMD) and carotid disease, both of which demonstrated significant association in meta-analyses. These relationships
remained consistent within age, study quality, methods of
assessing ED, and publication year subgroups. Importantly,
ED, when identified by a simple five-item questionnaire
(IIEF-5), shows similar relationships with endothelial dysfunction and carotid atherosclerosis as the longer form of
the questionnaire (IIEF-15). This underscores the IIEF-5
utility for identifying persons at risk of subclinical CVD.
Although age accounted for some heterogeneity between
FMD studies, participants in all age groups demonstrated a
significant association of ED with subclinical CVD. This is
particularly important in younger men who are less likely
to be screened for subclinical CVD and who may be presenting to a provider for the first time with symptoms
related to ED. Our study findings indicate that such men are
at greater risk of having identifiable subclinical CVD and
will benefit from an active CVD work-up.

Coronary artery calcium, an assessment that is most predictive of coronary artery disease, had varying results as
only two of the five studies showed an association with ED.
Most of the CAC studies had small sample sizes (most
studies had less than 200 participants), which may limit a
study’s ability to detect small differences between groups
and may account for the lack of association seen. Thus,
there is inconclusive evidence to either prove or refute an
association between ED and CAC, and larger studies are
needed.
Among the measures of vascular stiffness, ABI had
conflicting associations with ED, while ED was consistently associated with lower TBI and increased BAPWV.
We note that both studies with no significant associations
of ED with ABI were conducted among primarily diabetic
participants. Previous studies among diabetic individuals
have shown that ABI is a poor marker of cardiovascular
disease mortality and that TBI has a better predictive
value.56,57 Thus, among the non-ABI studies, ED appears
to identify peripheral vascular stiffness (irrespective of
diabetic status) as all the studies showed a significant relationship with markers of peripheral vascular function. In
addition, all three studies in non-diabetic populations
showed a significant association between ED and peripheral vascular function.51–53 Summed together, our findings
suggest that ED is associated with peripheral vascular disease and that non-ABI measures may be important tools in
the assessment of persons with diabetes and ED. We would
also emphasize that ABI has been demonstrated to be a
poor measure of vascular stiffness in diabetic participants.56–58 More studies are required on the measures of
central arterial function, as we found only one study that
measured the AoPWV.28
It is thought that endothelial dysfunction, an early marker
of atherosclerosis, is also one of the earliest abnormalities
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Table 2. Summary of stratified meta-analyses assessing the association of ED with FMD and cIMT.
FMD
Variable

Subgroup

Study no.

Population
total (n)

MD for subgroup
analyses (CI)

I² (%)

p for subgroup
differences

Mean age of study
population in years

<40
40–50
>50
≥7
<7
IIEF-15
IIEF-5
Before 2010
2010 and after

3
5
7
6
9
5
10
7
8

680
507
838
1033
992
418
1607
570
1455

–4.55 (–5.41, –3.70)
–1.19 (–1.85, –0.52)
–2.51 (–3.14, –1.87)
–1.53 (–2.31, –0.75)
–3.70 (–4.43, –2.98)
–2.99 (–4.01, –1.96)
–2.61 (–3.26, –1.97)
–2.69 (–3.51, –1.87)
–2.80 (–3.58, –2.01)

71
75
97
94
98
96
98
96
98

Ref
<0.001
<0.001
Ref
<0.001
Ref
0.542
Ref
0.850

Variable

Subgroup

Study no.

Population
total (n)

MD for subgroup
analyses (CI)

I²

p for subgroup
differences

Mean age of study
population in years

<40
40–50
>50
≥7
<7
IIEF-15
IIEF-5
Before 2010
2010 and after

3
3
6
8
4
5
7
4
8

680
172
412
791
473
305
959
243
1021

0.08 (0.03, 0.13)
0.05 (0.00, 0.11)
0.11 (0.07, 0.16)
0.10 (0.05, 0.14)
0.08 (0.02, 0.13)
0.07 (0.02, 0.11)
0.10 (0.06, 0.13)
0.05 (0.02, 0.09)
0.11 (0.07, 0.14)

0
45
55
70
63
74
0
65
10

Ref
0.450
0.380
Ref
0.582
Ref
0.276
Ref
0.117

Study quality
ED assessment
Publication year
cIMT

Study quality
ED assessment
Publication year

CI, confidence interval; cIMT, carotid intima–media thickness; ED, erectile dysfunction; FMD, flow-mediated dilatation; I2, heterogeneity; MD, mean difference; IIEF, International Index of Erectile Function.

Figure 3. Meta-analysis of studies on the relationship between erectile dysfunction (ED) and carotid intima–media thickness (cIMT).
Results are shown as differences in mean cIMT (in mm) between ED and non-ED groups and their pooled mean difference (MD).
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Table 3. Summary of subclinical atherosclerosis measures and their association with ED.a
First author, publication
year

Type of study, population description

Measures

ED assessment

Results

Kaiser et al., 200428

Case–control (subjects with ED,
n=30, mean age, 46.6; subjects
without ED, n=27, mean age, 46.2)
Case–control (subjects with ED,
n=30, mean age, 46.6; subjects
without ED, n=27, mean age, 46.2)

AoPWV

IIEF-15

Aortic PWV was found to be similar
between the two groups

CAC

IIEF-15

Chiurlia et al., 200529

Case–control (subjects with ED,
n=70, mean age, 50.9; subjects
without ED, n=73, mean age, 50.1)

CAC

IIEF-5

Guaraldi et al., 201237

Cross-sectional (HIV-infected
subjects with ED, n=79, mean age,
50.06; without ED, n=54, mean age,
47.48)
Case–control (subjects with ED,
n=60, mean age, 55.7; subjects
without ED, n=23, mean age, 53.2)

CAC

IIEF-15

Abnormal calcium scores
(considered >5) were found in 27%
of ED subjects and 20% of subjects
without ED. No p-value reported,
estimated p-value = 0.55.
High CAC levels (defined as >65)
were present in 51.4% of ED
subjects and 15.1% of subjects
without ED (p<0.001)
CAC>100 was present in 8 (10%)
patients with ED and 5 (9%) patients
without ED (p=0.87)

CAC

IIEF-15

Kaiser et al., 200428

Yaman et al., 200749

Inci et al., 200850

Cross-sectional (chronic renal failure CAC
subjects with ED, n=29; without ED,
n=6; mean age, 51.6)

IIEF-5

Chai et al., 200951

Cross-sectional (subjects with ED,
n=122, subjects without ED, n=63;
mean age, 71)

IIEF-5

Polonsky et al., 200952

Cross-sectional, referral based
ABI
(subjects with ED, n=311, mean age,
60.9; subjects without ED, n=370,
mean age, 54.4)
Cross-sectional (subjects with ED,
BAPWV
n=95, mean age, 67; subjects without
ED, n=185, mean age, 54)

IIEF-15

Cross-sectional (Type 2 diabetics
with ED, n=183, without ED, n=14;
mean age, 64.6)
Cross-sectional (Type 2 diabetics
with ED, n=183, without ED, n=14;
mean age, 64.6)

ABI

IIEF-5

BAPWV

IIEF-5

Cross-sectional (Type 2 diabetics
with ED, n=183, without ED, n=14;
mean age, 64.6)
Cross-sectional (men treated for HT
and diabetes, Type II, with ED, n=82,
mean age, 56.7; without ED, n=32,
mean age, 56.8)

TBI

IIEF-5

ABI

IIEF-15

Imai et al., 201053

Fukui et al., 201154
Fukui et al., 201154

Fukui et al., 201154
Severo et al., 201455

TBI

IIEF-5

Significantly higher CAC burden was
seen in persons with ED (mean CAC
in subjects with ED, 325.5; without
ED, 10.1) (p<0.0001)
Among persons without known
coronary heart disease, those with
ED had a greater but non-statistically
significant CAC score (ED vs no ED
median CAC score: 71.2 vs 17.5,
p>0.05)
Lower TBI was found to be
significantly and independently
associated with more severe ED
(β= 0.422; 95% CI: 0.019, 0.826)
Subjects with ED had a twofold
higher prevalence of PAD (ABI≤0.9)
than men without ED (32% vs 16%,
p<0.001)
Persons with mild to no ED
averaged 1523±322 cm/sec, while
those with moderate to severe
ED averaged 1855±470 cm/sec
(p<0.001)
No significant correlation was found
between ABI and ED
PWV score was inversely related
with IIEF-5 score (r=−0.255,
p=0.0003). Among subjects 60–69
years old, r=−0.290, p=0.0018
Higher TBI was found to be
associated with a higher IIEF-5 score
(r=0.483, p=0.0005)
No significant correlation was found
between ABI and ED (ED ABI: 1.13,
no ED ABI: 1.11; p=0.37)

aMeasures not included in meta-analysis.
ED, erectile dysfunction; ABI, ankle–brachial index; AoPWV, aortic pulse wave velocity; BAPWV, brachial–ankle pulse wave velocity; CAC, coronary
artery calcium; HIV, human immunodeficiency virus; HT, hypertension; IIEF, International Index of Erectile Function; PAD, peripheral artery disease; TBI,
toe–brachial index.

seen in persons with ED.40 Therefore, persons with ED and
endothelial dysfunction may benefit from aggressive CVD
preventive management, even if there are no other obvious

CVD risk factors (as may be seen in young persons with
ED). On the other hand, ED also identifies markers of
advanced subclinical vascular disease such as ABI and TBI,
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especially among men without diabetes. This is particularly
significant as men without diabetes are probably less likely
to be assessed for peripheral artery disease, especially if they
are asymptomatic like those in the studies. Considering the
significant morbidity and mortality burden associated with
peripheral vascular disease,59 our results suggest that ED
may be a marker of subclinical CVD and atherosclerosis,
even in patients without an overt diagnosis of peripheral vascular disease. ED may be used to identify patients who may
benefit from early screening for vascular dysfunction.
Both ED and increased cIMT are predictive of stroke.60,61
Thus, our findings in which there is increased cIMT in persons with ED support earlier findings from prospective
studies on ED and stroke, and suggest that cIMT assessment in persons with ED may improve stroke risk
stratification.
ED and CVD are thought to share common mechanisms. Both disorders are associated with increasing age,
alcohol use, smoking, obesity, diabetes, and sedentary
lifestyle.19 These risk factors are strongly associated with
conditions contributing to poor vascular flow, such as
endothelial dysfunction and atherosclerosis. Our finding,
in which there is a consistent association of ED with three
of the four domains of subclinical CVD we assessed
(endothelial dysfunction, carotid atherosclerosis, and
other markers of vascular function), further supports the
theory of shared mechanisms between ED and CVD.
However, longitudinal relationships would need to be
assessed to further define the pathogenetic role atherosclerosis plays in ED.
Previous studies have demonstrated the utility of CVD
risk reduction (through lifestyle changes and/or statins) in
improving ED; however, the benefits of CVD risk reduction on ED improvement are still not widely publicized,
especially to men who are less likely to participate in lifestyle improvement programs.62–64 Our study supports a
more aggressive CVD risk assessment and management
of persons with ED, including among young men who
may otherwise have been categorized as low risk due to
their young ages. The measures of subclinical disease
included in this review (with the exception of CAC) can
be assessed by non-invasive office-based procedures with
no radiation risk and whose results can be available during a clinic visit. Such easy-to-conduct tests coupled with
the ability to identify ED through the use of a short questionnaire (IIEF-5) make ED identification and subsequent
assessment of subclinical CVD feasible in a primary care
office setting.

Limitations
One of the weaknesses of our review is that all the studies
in this review are either cross-sectional or case–control in
design. This is reflected in the relatively low scores in quality that the studies in this review received. As such, we are
unable to assess the temporal relationship between ED and
subclinical CVD. Additionally, we are unable to control for
many covariates such as hormone levels, diet (which may
affect hormone levels), disorders resulting in cavernosal
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fibrosis, kidney function, depression status or medication
use, which were not adjusted for or reported in most of the
studies. These conditions also cause ED and are not necessarily vascular and may serve as potential confounders. The
absence of patient-level data on participants who are on
optimal guideline-directed CVD therapy makes it impossible to account for the effect of prevention interventions on
the relationship between ED and CVD. Other weaknesses
include a significant heterogeneity of values within the
studies in the meta-analysis. Sensitivity analysis excluding
the most outlier studies did not significantly change statistical heterogeneity among the FMD studies. However,
among the cIMT studies, this analysis showed a decline of
the I2 to 0 without a significant change in the absolute mean
difference. We could not determine the source of this heterogeneity, even after conducting subgroup analysis.
Reasons for this may be the very diverse populations
included across the studies, some assessments being operator dependent (such as FMD), or differences in how cardiovascular disease risk assessments are organized and
reported. Age and study quality only contributed partly to
the heterogeneity between studies, as demonstrated in our
subgroup meta-analyses. We were unable to account for
intra-study differences in age as the subgroup analyses only
accounted for age differences across (but not within) studies. Other unaddressed sources of heterogeneity include
the inter-operator (and possibly intra-operator) differences
that were likely to have occurred in these studies. This may
be more prominent for the brachial artery FMD measurement, which is heavily user dependent and which did not
have a uniform standard of measurement (as noted in the
Methods section). Unfortunately, we are unable to assess
or account for these differences in our meta-analyses. Our
assessment of funnel plot asymmetry suggests an increased
likelihood of publication bias among the FMD and cIMT
studies.

Conclusion
This study demonstrates an association between ED and
measures of subclinical CVD, shedding more light on the
relationship between ED and CVD, and suggests that ED
may be useful in CVD risk stratification. Future research
should focus on determining the longitudinal relationship
between ED and subclinical CVD and should involve larger
sample sizes. As coronary artery calcification testing
becomes more common, larger studies on its relationship
with ED should also be conducted.
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